Clinical Trials · NCT02143713
Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated Pain
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AbbVie
- Enrollment
- 496
- Start date
- May 2014
- Locations
- See registry
- Primary endpoint
- Percentage of Participants With a Response for Dysmenorrhea at Month 6 Based on Daily Assessment